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Competition-based, quantitative chemical
proteomics in breast cancer cells identifies
new target profiles for sulforaphane†
James A. Clulow,‡a Elisabeth M. Storck,‡a Thomas Lanyon-Hogg, ‡a
Karunakaran A. Kalesh, a Lyn H. Jones b and Edward W. Tate*a
Sulforaphane is a small molecule isothiocyanate which exhibits
anticancer potential, yet its biological targets remain poorly understood.
Here we employ a competition-based chemical proteomics strategy to
profile sulforaphane’s targets and identify over 500 targets along with
their relative aﬃnities. These targets provide a new set of mediators
for sulforaphane’s bioactivity, and aid understanding of its complex
mode of action.
Isothiocyanates are a class of bioactive, electrophilic compounds
that are produced from metabolism of glucosinolates found in
many cruciferous vegetables. Promising in vitro cell culture and
in vivo animal studies for this compound class have led to intense
research interest.1 One such isothiocyanate, ()-1-isothiocyanato-
(4R)-(methylsulfinyl)-butane (sulforaphane), has been particularly
well studied owing to its potential anti-cancer activity. Sulforaphane
has been suggested to prevent or suppress the development ofmany
types of cancer, including breast cancer;2,3 its properties have been
explored in over 1500 publications and many registered clinical
trials, including ongoing trials of a stabilised sulforaphane–cyclo-
dextrin complex in breast cancer. Sulforaphane can covalently
modify proteins, as well as other biomolecules, and is widely
appreciated to be a polypharmacological agent that likely affects
multiple targets and signalling cascades.4,5 A small number
of well-characterised protein targets have been identified for
sulforaphane that provide an initial basis for explaining its
cellular activities;6 however, despite growing interest in sulforaphane
and its potential therapeutic application, its molecular targets and
underlying mode of action remain poorly characterised.
Understanding the full protein target spectrum of sulfora-
phane could provide greater insight into its mode of action. The
eﬀect of sulforaphane treatment on cellular protein levels has
previously been analysed by proteomic strategies;7–9 however,
investigations into alterations in protein expression and/or
degradation do not provide insight into direct target binding.
Attempts to profile the covalent target spectrum of sulforaphane
have employed sulforaphane probes labelled with radioisotopes
or bioorthogonal alkyne reporters.8,10 Analysis of radiolabelled
targets by 2D PAGE followed by proteomic identification has a
strong bias towards highly abundant targets. In contrast,
advances in the use of ‘click’ chemistry functionalisation of
bioorthogonal reporters allow for a range of analysis, including
global proteomic profiling.11 To date, however, a comprehensive
and unbiased screen of sulforaphane’s targets in a relevant
cancer system is still lacking. We therefore sought to employ a
quantitative, competition-based chemical proteomics strategy to
profile sulforaphane’s targets in two breast cancer cell lines, and
to identify the relative affinities of these targets for sulforaphane.
Ahn et al. previously reported the synthesis and application
of cell-permeable alkyne-tagged sulforaphane probe 1 (Fig. 1a);10
the electrophilic isothiocyanate group is replaced with sulfoxy-
thiocarbamate, as the product of thiol addition to the latter is
more stable. Sulforaphane’s sulfoxide moiety can be replaced with
a ketone without aﬀecting activity.10 1 was reported to identify over
100 protein targets in HEK293 cells by mass spectrometry (MS);
however, only two targets of this probe have been validated as
genuine sulforaphane targets (macrophage migration inhibitory
factor (MIF) and AKAP149), and profiling was not performed in
cancer cell lines.10 We therefore synthesised 1 alongside a novel
probe 2 (Fig. 1a) with greatly reduced steric encumbrance
around the electrophilic warhead. 2 was synthesised using a
modified procedure to introduce the alkyne handle in a short
synthetic sequence from propargylamine (Schemes S1 and S2,
ESI†). Sulforaphane and 2 display similar lipophilicity (clogP =
0.15 and 0.62, respectively), which is significantly lower than
probe 1 (clogP = 2.7). This improvement in probe lipophilicity
(DclogP = 3.3) was expected to impart reduced non-specific
binding to 2. Probe 1 has already been shown to exert similar
biological eﬀects to sulforaphane,10 suggesting 2 would also
mimic this biological activity. MCF7 and MDA-MB-231 breast
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cancer cell lines were selected as biologically relevant systems
for treatment with 1 and 2. Following in-cell labelling with each
probe, cells were lysed and probe-labelled proteomes functionalised
with azido-TAMRA capture reagent12 to specifically visualise covalent
targets, using well-established copper-catalysed alkyne–azide
cycloaddition (CuAAC) methodology.13 Proteomes were resolved
by SDS-PAGE and analysed by in-gel fluorescence (Fig. 1). To
determine the extent to which sulforaphane shares the same
target profile as each probe, competition assays were performed
whereby cells were incubated with sulforaphane prior to probe
treatment. Sulforaphane concentration-dependent reduction in
labelling by 1 and 2 was observed for the majority of bands,
suggesting a high degree of target overlap (Fig. 1). Competition
assays against other electrophilic alkylating agents (iodoacetamide
and N-ethylmaleimide) indicated common target reactivity with
the probes. The sulforaphane-mimetic probe 2 showed the most
robust competition by sulforaphane (Fig. 1).
To identify the protein targets of sulforaphane we employed
‘spike-in’ stable isotopic labelling of amino acids in cell culture
(SILAC) methodology coupled with competition-based chemical
proteomics.14 Sulforaphane exerts biological activity at low mM
concentrations in MCF7 and MDA-MB-231 cell lines,15 therefore
cells were cultured under normal conditions and treated with 2
(5 mM) alone, or 2 (5 mM) plus sulforaphane (5, 25 or 100 mM) for
30 min. In parallel, the cell line of interest was labelled with
DMEM media containing 15N4
13C6-arginine and
15N2
13C6-lysine
(R10K8) over multiple passages until incorporation of R10K8
was 498% (Tables S1 and S2, ESI†). R10K8-labelled cells were
treated with 2 (20 mM) for 30 min, and lysed to generate a ‘spike-in’
SILAC lysate. A fixed amount of this ‘spike-in’ lysate was added to
each competition lysate and the mixed lysates functionalised by
CuAAC with an azido-biotin capture reagent.16 Labelled proteins
were aﬃnity enriched on neutravidin-sepharose, reduced, alkylated
and trypsin digested, and the resulting peptides analysed by LC-MS/
MS to identify protein targets and quantify enrichment levels across
the sulforaphane concentration gradient, using the ‘spike-in’ SILAC
peptide as an internal standard to generate heavy/light (H/L) ratios
(Fig. 2a). Medium-confidence targets were defined as those giving a
statistically significant (t-test, S0 = 1, FDR = 0.01) increase in H/L
ratio compared to samples treated with 2 only (Fig. S1–S3, ESI†).
High-confidence targets were defined asmedium-confidence targets
present at 5, 25 and 100 mM, or 25 and 100 mM sulforaphane
competition (Fig. S4, ESI†). This identified 121 and 129 high-
confidence targets in MDA-MB-231 and MCF7 cells, respectively
(Fig. 2b), with 56 conserved targets (Fig. 2c and Tables S3 and S4,
ESI†). Analysis of published target abundances indicates that
the difference in target profile between cell lines may relate to
differences in expression levels of target proteins (Fig. S5, ESI†).
The most potent sulforaphane binders were identified through
analysis of relative amounts of target captured by 2 over three
sulforaphane concentrations (Fig. 2b). Targets exhibiting strong
competition for probe labelling at the lowest sulforaphane
concentration were hypothesised to be the most potent binders
(Fig. 2b). Across both cell lines these included Kelch-like ECH-
associated protein 1 (KEAP1) and MIF. KEAP1 is a repressor of
the nuclear factor (erythroid-derived 2)-like 2 (Nrf2) transcription
factor controlling antioxidant response element (ARE)-driven gene
expression,17 whilst MIF is a pro-inflammatory cytokine, whose
expression in cancer correlates with tumour aggressiveness and
metastatic potential.18 Both proteins have been previously identified
as sulforaphane targets;17,18 however, this is the first time their
interaction with sulforaphane has been observed in a cellular
environment at endogenous expression levels. Identification of
known sulforaphane targets demonstrates the validity of our
approach, and provides the first assessment of the binding of
sulforaphane towards these two targets relative to other proteins
in the cell, in the absence of artificial overexpression. Sulforaphane
is often used as a chemical probe inhibitor of KEAP1; however,
our results indicate very substantial target promiscuity at higher
concentrations.
Sulforaphane’s targets were globally assessed using the bio-
informatic platform Ingenuitys Pathway Analysis. The major
canonical pathway upregulated in a dose-dependent manner in
both cell lines was apoptosis signalling (Fig. S6, ESI†), consistent
with sulforaphane’s ability to induce apoptosis in numerous
cancer cell lines at elevated concentrations.19 In both cell lines a
common apoptosis signalling target was NF-kB subunits (Fig. S7,
ESI†). NF-kB is a ubiquitous transcription factor controlling
gene expression of a variety of pro-inflammatory mediators,
Fig. 1 (a) Structures of sulforaphane and probes 1 and 2. The electrophilic
moiety of each molecule is highlighted in blue, and the bioorthogonal
alkyne handle in red. (b) MCF7 and (c) MDA-MB-231 lysate in-gel fluorescence
and coomassie staining after in-cell labelling with 1 or 2, competed
against a concentration gradient of sulforaphane, iodoacetamide (IAA),
or N-ethylmaleimide (NEM).
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and activation is linked to cancer cell survival.20 Proposed
mechanisms for sulforaphane inhibition of NF-kB include
interference with an activating kinase IkBa,21 reduced NF-kB
upstream signalling,22 or direct interaction with NF-kB p50
subunit.23 Our data shows sulforaphane binds two other
NF-kB subunits p65 (RELA, high-confidence in both lines)
and p52 (NFKB2, medium- and high-confidence in MCF7 and
MDA-MB-231, respectively). Other conserved apoptosis signalling
targets include DFFA, PLCG1, and RPS6KA1; apoptosis signalling
targets such as BID and ROCK1 were only identified in one cell
line (Fig. 3a). Sulforaphane mediates apoptosis in a cell line-
specific manner through diﬀerent apoptotic pathways;19 these
diﬀerences in target profile between MCF7 and MDA-MB-231
may explain such eﬀects.
Major downregulated canonical pathways included growth
hormone and ERK/MAP kinase signalling pathways (Fig. S6, ESI†),
which have been identified as targeted by sulforaphane.24,25
Several downregulated pathways are mediated via the signal
transducer and activator of transcription (STAT) 1 and 3 proteins
(Fig. S8, ESI†). STAT3 was a high-confidence target in both lines,
and STAT1 a high-confidence and medium-confidence target
in MCF7 and MDA-MB-231, respectively. STAT proteins are
latent cytosolic transcription factors; STAT3 in particular is an
oncogenic transcription factor constitutively expressed in a
variety of cancers, resulting in expression of various genes
involved in cell proliferation.26 STAT1 and STAT3 were therefore
validated as sulforaphane targets via labelling with 2 in competition
with sulforaphane, followed by CuAAC functionalisation, pull-down
and western blot analysis (Fig. 3b, c and Fig. S9, ESI†). Sulforaphane
inhibition of STAT3 signalling has been reported previously, with
the proposed mechanism of action through reduction in protein
level and phosphorylation status of STAT3’s activator kinase, JAK2.27
Our data show sulforaphane also directly binds STAT1 and STAT3.
Disease and biofunction analysis of sulforaphane’s targets
indicated upregulation of organismal death (40 targets in MCF7
and 34 in MDA-MB-231) and downregulation of cell proliferation
(58 targets in MCF7) and cell viability (24 targets in MDA-MB-231)
with sulforaphane treatment (Fig. S10–S12, ESI†). Common in
these functions were high-affinity, high-confidence conserved
targets serine/threonine kinase (STK) 3 and 4, which function in
the Hippo pathway to regulate cell proliferation and apoptosis.28
Fig. 2 (a) ‘Spike-in’ SILAC workflow. 2 in competition with a sulforaphane
(SULF) concentration gradient was incubated with cells grown in normal
media, and R10K8 labelled cells were treated with 2 only. Cells were lysed,
and ‘spike-in’ R10K8 lysate labelledwith 2 added to light lysates. Probe-bound
proteins were functionalised by CuAAC, aﬃnity enriched and digested for
LC-MS/MS. Heavy/light ratios (R(0)–R(100)) were calculated and quantification
scores (QS) generated as a ratio of ratios to the probe only sample. (b) Heat
maps showing log2(QS) over four sulforaphane concentrations (0, 5, 25 and
100 mM). Blue = no competition, red = high competition. (c) Distribution of
unique and common high-confidence targets.
Fig. 3 (a) Scatter plot of log2(QS) for selected targets across three
concentrations of sulforaphane competition (5, 25, and 100 mM). Targets
were given a value of 0 when absent from a cell line. (b) MCF7 and
(c) MDA-MB-231 western blot analysis showing STAT1 and STAT3 are targets
of 2 and sulforaphane labelling competition and pull-down. L = lysate,
SN = supernatant, PD = pull-down.
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The conserved target profile between cell lines similarly
aﬀected apoptotic and growth signalling, with corresponding
upregulation of cell death biofunctions (Fig. S13, ESI†). Analysis
of the interaction network of conserved targets highlighted a
high degree of connectivity around Akt protein kinases and
caspases (Fig. S14, ESI†). Although neither are identified as a
direct target of sulforaphane in our study, previous studies have
shown sulforaphane can downregulate total and phosphorylated Akt
levels leading to antiproliferative eﬀects,29 and promote activation of
various caspases in apoptosis.19 Our target profile therefore identifies
several potential mediators of these eﬀects.
The presented dataset represents the most comprehensive
direct target profile of sulforaphane to date, and highlights the
wide range of targets that sulforaphane covalently binds. It
should, however, be noted that use of sulfoxythiocarbamate
warheads in electrophilic probes may aﬀect target reactivity or
target labelling dependent on transient metabolic modification,
for example by glutathionylation. Sulforaphane induces varied
biological eﬀects at diﬀerent concentrations,30 and our quantitative
data provides insight into how such eﬀects could be mediated
by demonstrating targets that engage sulforaphane at diﬀerent
therapeutically relevant concentrations. These target profiles are
orthogonal datasets that complement general proteomic and
transcriptomic studies of sulforaphane treatment,8 and will
provide a valuable starting point for future studies.
Target profile diﬀerences between the two cell lines high-
light the potential for sulforaphane to diﬀerentiate between breast
cancers based on molecular mechanism. The use of cleavable
capture reagents may also allow identification of sulforaphane
binding sites in future. Increased understanding of sulforaphane’s
targets and underlying mode of action may ultimately provide
better insight into how best to apply this agent or related electro-
philic compounds in the clinic.
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